兰尼单抗联合全视网膜光凝与单纯全视网膜光凝治疗高危增殖性糖尿病视网膜病变(PROTEUS研究)
PROTEUS研究为前瞻性随机多中心开放标签II/III期研究,纳入87例高危增殖性糖尿病视网膜病变患者,比较兰尼单抗0.5mg玻璃体腔注射联合全视网膜光凝与单纯全视网膜光凝的疗效。12个月时联合组新生血管总面积减少者占92.7%,单纯光凝组占70.5%(P=0.009),联合治疗在新生血管消退方面更有效。
要点
- 12个月时联合组92.7%患者新生血管总面积减少,单纯光凝组70.5%(P=0.009)。
- 联合组新生血管完全消退43.9%,单纯光凝组25.0%(P=0.066,未达统计学显著)。
- 联合组12个月内平均全视网膜光凝次数3.5±1.3次,单纯光凝组4.6±1.5次(P=0.001)。
核心结论
- 在12个月随访中,兰尼单抗联合全视网膜光凝对高危增殖性糖尿病视网膜病变患者的新生血管消退比单纯全视网膜光凝更有效。
研究设计与样本
- 前瞻性、随机、多中心、开放标签、II/III期研究,纳入87例年龄≥18岁的1型或2型糖尿病合并高危增殖性糖尿病视网膜病变患者(平均年龄55.2岁,37%为女性)。
- 参与者按1:1随机接受兰尼单抗联合全视网膜光凝(n=41)或单纯全视网膜光凝(n=46);联合组接受3次每月兰尼单抗注射并联合标准全视网膜光凝,单纯光凝组在第1天至第2个月间接受标准全视网膜光凝,此后两组再治疗由研究者决定。
- 77例(88.5%)完成研究。
主要发现
- 第12个月时,联合组92.7%的患者新生血管总面积减少,单纯光凝组为70.5%(P=0.009)。
- 联合组视盘新生血管减少者占93.3%、其他部位新生血管减少者占91.4%,单纯光凝组分别为68.8%和73.7%,仅其他部位新生血管减少的差异有统计学意义(P=0.048)。
- 联合组新生血管总面积完全消退者占43.9%,单纯光凝组占25.0%(P=0.066)。
- 第12个月时联合组平均最佳矫正视力为75.2个字母(20/32),单纯光凝组为69.2个字母(20/40)(P=0.104)。
- 联合组12个月内平均全视网膜光凝治疗次数为3.5±1.3次,单纯光凝组为4.6±1.5次(P=0.001)。
关键数值与推荐
- 主要结局为第12个月时新生血管总面积(视盘新生血管加其他部位新生血管)较基线的任何减少。
- 次要结局包括最佳矫正视力变化、新生血管完全消退时间、新生血管复发、黄斑视网膜厚度变化、糖尿病黄斑水肿治疗需求、因玻璃体出血、牵拉性视网膜脱离或其他糖尿病视网膜病变并发症需玻璃体切割术的需求以及治疗相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Comparison of the efficacy of ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP alone in the regression of the neovascularization (NV) area in subjects with high-risk proliferative diabetic retinopathy (HR-PDR) over a 12-month period. DESIGN: Prospective, randomized, multicenter, open-label, phase II/III study. PARTICIPANTS: Eighty-seven participants (aged ≥18 years) with type 1/2 diabetes and HR-PDR (mean age, 55.2 years; 37% were female). METHODS: Participants were randomized (1:1) to receive RBZ+PRP (n = 41) or PRP monotherapy (n = 46). The RBZ+PRP group received 3 monthly RBZ injections along with standard PRP. The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators' discretion. MAIN OUTCOME MEASURES: The primary outcome was regression of NV total, on the disc (NVD) plus elsewhere (NVE), defined as any decrease in the area of NV from the baseline to month 12. Secondary outcomes included best-corrected visual acuity (BCVA) changes from baseline to month 12, time to complete NV regression, recurrence of NV, macular retinal thickness changes from baseline to month 12, need for treatment for diabetic macular edema, need for vitrectomy because of occurrence of vitreous hemorrhage, tractional retinal detachment or other complications of DR, and adverse events (AEs) related to treatments. RESULTS: Seventy-seven participants (88.5%) completed the study. Overall baseline demographics were similar for both groups, except for age. At month 12, 92.7% of participants in the RBZ+PRP group presented NV total reduction versus 70.5% of the PRP monotherapy participants (P = 0.009). The number of participants with NVD and NVE reductions was higher with RBZ+PRP (93.3% and 91.4%, respectively) versus PRP (68.8% and 73.7%, respectively), significant only for NVE (P = 0.048). Complete NV total regression was observed in 43.9% in the RBZ+PRP group versus 25.0% in the PRP monotherapy group (P = 0.066). At month 12, the mean BCVA was 75.2 letters (20/32) in the RBZ+PRP group versus 69.2 letters (20/40) in the PRP monotherapy group (P = 0.104). In the RBZ+PRP group, the mean number of PRP treatments over month 12 was 3.5±1.3, whereas in the PRP monotherapy group, it was 4.6±1.5 (P = 0.001). No deaths or unexpected AEs were reported. CONCLUSIONS: Treatment with RBZ+PRP was more effective than PRP monotherapy for NV regression in HR-PDR participants over 12 months.
引用
- Figueira J, Fletcher E, Massin P, et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018. PMID: 29395119. doi:10.1016/j.ophtha.2017.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。